Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
International Journal of Urology : Official Journal of the Japanese Urological Association|July 16, 2024
Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastasesSoichiro Yoshida, Yuya Maezawa, Kensaku Ishihara, et al.International Journal of Radiation Oncology, Biology, Physics|July 1, 2018
Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation TherapyHajime Tanaka, Soichiro Yoshida, Fumitaka Koga, et al.Clinical Genitourinary Cancer|January 28, 2025
Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study)Yuki Nakamura, Hajime Tanaka, Noboru Numao, et al.International Journal of Clinical Oncology|April 21, 2025
Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study)Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, et al.International Journal of Clinical Oncology|June 4, 2024
Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA studyKenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|June 4, 2025
Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study)Tomoki Kimura, Motohiro Fujiwara, Yuya Maezawa, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|May 12, 2026
Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA StudyHiroki Shimoda, Yuki Nakamura, Masaharu Inoue, et al.Japanese Journal of Clinical Oncology|March 16, 2026
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)Ichiro Yonese, Fumitaka Koga, Masahiro Toide, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|June 8, 2026
Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying EffectsShugo Yajima, Soichiro Yoshida, Shohei Fukuda, et al.International Urology and Nephrology|April 21, 2026
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinationsShugo Yajima, Soichiro Yoshida, Shohei Fukuda, et al.Pageof 6